Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma

Journal of Neuro-oncology
Penny FangJing Li

Abstract

Immune checkpoint inhibitors have demonstrated remarkable benefits in cancer patients. However, concern regarding toxicity in the setting of stereotactic radiosurgery (SRS) is often raised. In this study, we characterize radiation necrosis (RN) following immunotherapy and SRS. Melanoma patients treated with SRS and anti-CTLA-4 and/or anti-PD-1 at our institution from January 2006 to December 2015 were retrospectively reviewed. Overall survival (OS) and time to RN were assessed using Kaplan-Meier analysis. Logistic regression and Cox proportional hazards analyses were performed to identify predictors of radiation necrosis-free survival (RNFS) and RN risk. One-hundred thirty-seven patients with 1094 treated lesions over 296 SRS sessions were analyzed. Median follow-up was 9.8 months from SRS. Rate of RN was 27% of patients with median time to RN of 6 months. Median OS from SRS treatment was 16.9 months. RNFS at 6 months, 1 and 2 years was 92.7, 83.0, and 81.2%. Treatment with chemotherapy within 6 months of SRS was associated with worse RNFS at 1 year (78.4 vs. 87.5%, p = 0.017). On multivariate analysis, chemotherapy within 6 months and increased number of lesions treated were predictive of increased RN risk (HR 2.20, 95% CI 1.2...Continue Reading

References

Feb 18, 2014·Journal of Neuro-oncology·Paola QueiroloVanna Chiarion Sileni
Mar 11, 2015·International Journal of Radiation Oncology, Biology, Physics·Ana P KiessKathryn Beal
Aug 27, 2015·Journal of Neuro-oncology·Zachary A KohutekKathryn Beal
Dec 18, 2015·Journal for Immunotherapy of Cancer·Jonathan D SchoenfeldIrving D Kaplan

❮ Previous
Next ❯

Citations

Mar 10, 2018·Cancer Immunology, Immunotherapy : CII·Salvatore CaponnettoMarco Donia
Dec 6, 2018·American Journal of Clinical Oncology·Neha P AminCharles B Simone
Mar 5, 2019·Neuro-oncology·Sebastian F WinterJorg Dietrich
Oct 5, 2019·International Journal of Cancer. Journal International Du Cancer·Mark P van OpijnenEllen H W Kapiteijn
Sep 11, 2019·Journal of the National Cancer Institute·Florence JolyJanette Vardy
Sep 21, 2018·Frontiers in Oncology·Gokoulakrichenane LoganadaneAntonin Levy
Mar 5, 2019·Frontiers in Immunology·Hari MenonJames W Welsh
Jun 18, 2019·Therapeutic Advances in Medical Oncology·Gustavo SchvartsmanAntonio C Buzaid
Jun 7, 2018·Nature Reviews. Clinical Oncology·William L HwangJay S Loeffler
Jul 24, 2018·Therapeutic Advances in Neurological Disorders·Anna S Berghoff, Matthias Preusser
Sep 21, 2018·American Society of Clinical Oncology Educational Book·Hussein A TawbiGrant McArthur
Feb 23, 2019·Cancer Discovery·Grant M FischerMichael A Davies
Nov 17, 2019·Critical Reviews in Oncology/hematology·Fausto PetrelliAntonio Ghidini
Sep 6, 2020·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Norbert GalldiksCornelia Mauch
Jun 15, 2020·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Romain CarronJean-Jacques Grob
Mar 18, 2021·Clinical Oncology : a Journal of the Royal College of Radiologists·A WilkinsN Sundahl
Jun 8, 2021·Current Treatment Options in Oncology·Balamurugan A VellayappanSimon S Lo
Jun 12, 2021·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·Siujoon ChoiBrindha S Shivalingam
Oct 30, 2021·Breast Cancer Research and Treatment·Alice Y HoHeather L McArthur

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.